series-b
Stage
2020
Founded
3
Investors
About
Recode TX develops genetic medicines using a proprietary Selective Organ Targeting lipid nanoparticle platform to deliver gene therapies for rare diseases like cystic fibrosis and primary ciliary dyskinesia.
Explore Recode TX's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.